Pancreatic ductal adenocarcinoma (PDAC)


Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers and shows resistance to any therapeutic strategy used. Here we tested small-molecule inhibitors targeting chromatin regulators as possible therapeutic agents in PDAC. We show that JQ1, an inhibitor of the bromodomain and extraterminal (BET) family of proteins, suppresses PDAC development in mice by inhibiting both MYC activity and inflammatory signals. The histone deacetylase (HDAC) inhibitor SAHA synergizes with JQ1 to augment cell death and more potently suppress advanced PDAC. Finally, using a CRISPR-Cas9–based method for gene editing directly in the mouse adult pancreas, we show that de-repression of p57 (also known as KIP2 or CDKN1C) upon combined BET and HDAC inhibition is required for the induction of combination therapy–induced cell death in PDAC. SAHA is approved for human use, and molecules similar to JQ1 are being tested in clinical trials. Thus, these studies identify a promising epigenetic-based therapeutic strategy that may be rapidly implemented in fatal human tumors.


 Pancreatic ductal adenocarcinoma (PDAC)


Der Eintrag wurde am 27.09.2015 in der Rubrik Medizinische-NEWS eingetragen.


Falls Sie den Eintrag zu "Pancreatic ductal adenocarcinoma (PDAC)" ändern oder löschen wollen, kontaktieren Sie uns bitte per Email mit Angabe der URL "" oder der ID-Nummer "921".

Europa Apotheek: Ihre Versandapotheke mit den günstigen Medikamenten